Compare Regeneron Pharmaceuticals Inc (REGN) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Consumer Discretionary Select Sector SPDR Fund trades at $111.71 (market cap $21.87B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.5× Consumer Discretionary Select Sector SPDR Fund's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| REGN | XLY | |
|---|---|---|
Market Cap | $76.40B | $21.87B |
Volume | 626,381 | 6,695,862 |
Sector | Health | — |
52-Week High | $852.03 | $124.52 |
52-Week Low | $557.73 | $105.64 |
Typical Hold Time | 107 Days | 114 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
XLY trades at $111.36, down 0.35% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF has underperformed the consumer staples sector in 2026, declining over 7% year-to-date. Analyst consensus remains strongly positive with 100% buy ratings, though recent news highlights consumer discretionary sector challenges including inflation pressures and selective spending shifts.
The outlook remains cautiously optimistic given strong analyst support and potential benefits from 'funflation' trends, but persistent underperformance versus the S&P 500 and inflation sensitivity pose near-term headwinds. Key risks include consumer spending volatility and sector rotation pressures that could extend the current lagging performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
